The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis
Abstract
During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organization convened a workshop to review current knowledge and to develop guidelines for liposomal amphotericin B use for VL. In Europe, liposomal amphotericin B is widely used to treat VL. In Africa and Asia, the VL disease burden is high and drug access is poor; liposomal amphotericin B is available only through preferential pricing for nonprofit groups in East Africa. Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL. Combination trials in areas with antileishmanial drug resistance, and treatment and secondary prophylaxis trials in VL-human immunodeficiency virus-coinfected patients, are important to safeguard the current armamentarium and to optimize regimens. The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The increase in risk factors for leishmaniasis worldwide
Desjeux, P. (2001) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(01)90223-8 · Cited by 1,043
Sundar, S., More, D. K., Singh, M. K., Singh, V. P., Sharma, S., Makharia, A., Kumar, P. C. K., & Murray, H. W. (2000) · Clinical Infectious Diseases · doi:10.1086/318121 · Cited by 664
Self-citationTropical Infectious Diseases: Principles, Pathogens, and Practice
White, A. C., Atmar, R. L., & Greenberg, S. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-2-200001180-00025 · Cited by 578
Walsh, T. J., Goodman, J. L., Pappas, P., Bekersky, I., Buell, D. N., Roden, M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401
Deray, G. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.37 · Cited by 400
Meyerhoff, A. (1999) · Clinical Infectious Diseases · doi:10.1086/515085 · Cited by 295
Risk Factors for Kala-Azar in Bangladesh
Bern, C., Hightower, A. W., Chowdhury, R., Ali, M., Amann, J., Wagatsuma, Y., Haque, R., Kurkjian, K., Vaz, L. E., Begum, M., et al. (2005) · Emerging Infectious Diseases · doi:10.3201/eid1105.040718 · Cited by 215
Self-citationLiposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial
(1994) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068903 · Cited by 195
Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid Formulations
Sundar, S., Mehta, H., Suresh, A. V., Singh, S. P., Rai, M., & Murray, H. W. (2004) · Clinical Infectious Diseases · doi:10.1086/380971 · Cited by 189
Self-citationCollin, S., Davidson, R., Ritmeijer, K., Keus, K., Melaku, Y., Kipngetich, S., & Davies, C. (2004) · Clinical Infectious Diseases · doi:10.1086/381203 · Cited by 180
Self-citation
Cited by
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., Alvar, J., & Boelaert, M. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1748 · Cited by 1,490
Self-citationThe Relationship between Leishmaniasis and AIDS: the Second 10 Years
Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Cañavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., López-Vélez, R., & Moreno, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00061-07 · Cited by 937
Self-citationAmphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks275 · Cited by 775
Kinetoplastids: related protozoan pathogens, different diseases
Stuart, K., Brun, R., Croft, S., Fairlamb, A., Gürtler, R. E., McKerrow, J., Reed, S., & Tarleton, R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33945 · Cited by 604
Metadata
- Authors
- Bern, C., Adler‐Moore, J., Berenguer, J., Boelaert, M., Boer, M. D., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., Rosenthal, E., Royce, C., Russo, R., Sundar, S., & Alvar, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-10
- Volume
- 43
- Issue
- 7
- Pages
- 917-924
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2143697569
- Cited by
- 345
- References
- 33
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis. https://app.cochat.ai/papers/10.1086/507530
- The paper
- Bern, C., Adler‐Moore, J., Berenguer, J., Boelaert, M., Boer, M. D., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., Rosenthal, E., Royce, C., Russo, R., Sundar, S., & Alvar, J. (2006). Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis. Clinical Infectious Diseases. https://doi.org/10.1086/507530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.